10-K: SenesTech Reports FY2024 Results, Revenue Climbs with Evolve Product Launch

SenesTech's FY2024 revenue increased by 56% driven by the launch of its Evolve product line, while the company continues to manage operating losses.

Summary

• SenesTech, Inc. reported its financial results for the fiscal year ended December 31, 2024.
• The company's revenue increased by 56% to $1.857 million, compared to $1.193 million in 2023, primarily driven by the launch of the Evolve product line.
• Evolve products accounted for approximately 66% of the company's revenue in 2024.
• The company's cost of sales was $853,000, representing 45.9% of net sales, compared to $654,000, or 54.8% of net sales, in the previous year.
• Gross profit for 2024 was $1.004 million, with a gross profit margin of 54.1%, compared to $539,000 and 45.2% in 2023.
• Research and development expenses increased to $1.712 million from $1.228 million in the prior year.
• Selling, general and administrative expenses decreased to $5.541 million from $7.043 million in the prior year.
• The company's net loss for the year was $6.184 million, compared to $7.710 million in 2023.
• As of December 31, 2024, the company's cash and cash equivalents were $1.307 million.
• The company has an accumulated deficit of $136.1 million as of December 31, 2024.
• The company expects to continue to incur significant expenses and operating losses for at least the next 12 months and will need additional funding to continue operations.

Sentiment

Score: 4

Explanation: While revenue increased, the company continues to operate at a loss and requires additional funding, indicating a mixed but overall slightly negative outlook.

Positives

• Revenue increased by 56% due to the successful launch of the Evolve product line.
• Gross profit margin improved from 45.2% to 54.1%.
• Net loss decreased from $7.710 million to $6.184 million.
• Selling, general and administrative expenses decreased by $1.5 million.

Negatives

• The company continues to incur significant operating losses.
• The company has an accumulated deficit of $136.1 million.
• The company's cash and cash equivalents are $1.307 million.
• The company expects to continue to incur significant expenses and operating losses for at least the next 12 months and will need additional funding to continue operations.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional capital.
• The company may need to delay, limit, or terminate commercialization and development efforts if additional financing is not available.
• The company's ultimate success depends on market acceptance, commercial viability, and profitability of its products.
• The company's ability to meet its working capital needs is uncertain.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for at least the next 12 months and will need additional funding to continue operations.

Industry Context

The report highlights the growing market for non-lethal pest control solutions, driven by increasing restrictions on traditional rodenticides and growing consumer awareness of environmental impacts. SenesTech's focus on fertility control aligns with this trend.

Comparison to Industry Standards

• It is difficult to compare SenesTech directly to industry standards due to its unique focus on fertility control rather than traditional rodenticides.
• Comparable companies in the pest control industry, such as Rollins, Inc. and Ecolab, primarily focus on traditional pest control methods and have significantly larger revenue streams.
• However, SenesTech's innovative approach may position it well in the long term as environmental regulations become stricter and demand for non-lethal solutions increases.

Legal Proceedings

• The company was involved in a legal matter that was settled in November 2023 for $185,000.
• Liphatech Inc. commenced an action against the company in December 2024 alleging breach of contract, misappropriation of trade secrets, unfair competition, and unjust enrichment.

Related Party Transactions

• In connection with consulting agreements in place a $4,200 cash payment was made during 2023 to the Kito Impact Foundation, of which the Chair of our board serves as chief executive officer.

Stakeholder Impact

• Shareholders face the risk of dilution if additional equity financing is pursued.
• Employees face uncertainty regarding job security if the company is unable to secure additional funding.
• Customers may be impacted if the company is forced to delay or terminate product development or commercialization efforts.
• Creditors face increased risk if the company's financial condition does not improve.

Next Steps

• Continue to seek additional financing.
• Focus on marketing and sales of ContraPest and Evolve.
• Explore strategic partnerships.
• Seek additional regulatory approvals.
• Further develop manufacturing processes.
• Continue product enhancement and evolution of ContraPest and Evolve.
• Advance research and development activities.

Key Dates

Keywords

SenesTech, Evolve, ContraPest, revenue, financial results, fertility control, pest management, operating loss, net loss, gross profit, cash flow, financial statements